Toll-like Receptor 9 Antibody [M15F23]

Application: Reactivity: Human

Lane 1: Ramos, Lane 2: Raji

Usage Information

Dilution
WB1:1000 IP1:50 IF1:400-1:1600 FCM1:100-1:400

Application
WB, IP, IF, FCM

Reactivity
Human

Source
Rabbit Monoclonal Antibody

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW
130 kDa

Datasheet & SDS

Biological Description

Specificity
Toll-like Receptor 9 Antibody [M15F23] detects endogenous levels of total Toll-like Receptor 9 protein.

Clone
M15F23

Synonym(s)
Toll-like receptor 9; CD289; TLR9

Background
Toll-like receptor 9 belongs to the Toll-like receptor family of pattern recognition receptors and functions primarily as an intracellular sensor for microbial DNA. It possesses an extracellular leucine-rich repeat domain for ligand recognition and a cytoplasmic Toll/interleukin-1 receptor domain that recruits adaptor proteins. TLR9 localizes to the endoplasmic reticulum and undergoes proteolytic cleavage in endolysosomal compartments to generate a mature form capable of ligand binding at acidic pH in resting cells. Unmethylated CpG-containing DNA binds directly to the cleaved TLR9 ectodomain, inducing dimerization and recruitment of MyD88 along with TIRAP to form a signaling complex that activates IRAK4 and IRAK1 kinases. Phosphorylated IRAKs associate with TRAF6, which undergoes K63-linked auto-ubiquitination to activate TAK1, leading to IKK complex phosphorylation and subsequent IκBα degradation, thereby enabling NF-κB nuclear translocation and transcription of proinflammatory cytokines including TNF-α, IL-6, IL-12, and type I interferons. TLR9 signaling also engages the MAPK cascade through p38, JNK, and ERK phosphorylation, amplifying AP-1 activity to coordinate innate immune responses in plasmacytoid dendritic cells, macrophages, and B cells. MyD88-independent TRIF-mediated activation contributes to IRF7 phosphorylation and interferon-β production upon prolonged stimulation. Trafficking from ER through Golgi to lysosomes requires UNC93B1 chaperone activity, with endosomal acidification essential for ligand access and signal initiation. Expression predominates in immune cells, with isoforms arising from alternative splicing influencing ligand specificity. Dysregulation through polymorphisms or overexpression links TLR9 to autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis, where self-DNA recognition drives chronic inflammation.

Background

Toll-like receptor 9 belongs to the Toll-like receptor family of pattern recognition receptors and functions primarily as an intracellular sensor for microbial DNA. It possesses an extracellular leucine-rich repeat domain for ligand recognition and a cytoplasmic Toll/interleukin-1 receptor domain that recruits adaptor proteins. TLR9 localizes to the endoplasmic reticulum and undergoes proteolytic cleavage in endolysosomal compartments to generate a mature form capable of ligand binding at acidic pH in resting cells. Unmethylated CpG-containing DNA binds directly to the cleaved TLR9 ectodomain, inducing dimerization and recruitment of MyD88 along with TIRAP to form a signaling complex that activates IRAK4 and IRAK1 kinases. Phosphorylated IRAKs associate with TRAF6, which undergoes K63-linked auto-ubiquitination to activate TAK1, leading to IKK complex phosphorylation and subsequent IκBα degradation, thereby enabling NF-κB nuclear translocation and transcription of proinflammatory cytokines including TNF-α, IL-6, IL-12, and type I interferons. TLR9 signaling also engages the MAPK cascade through p38, JNK, and ERK phosphorylation, amplifying AP-1 activity to coordinate innate immune responses in plasmacytoid dendritic cells, macrophages, and B cells. MyD88-independent TRIF-mediated activation contributes to IRF7 phosphorylation and interferon-β production upon prolonged stimulation. Trafficking from ER through Golgi to lysosomes requires UNC93B1 chaperone activity, with endosomal acidification essential for ligand access and signal initiation. Expression predominates in immune cells, with isoforms arising from alternative splicing influencing ligand specificity. Dysregulation through polymorphisms or overexpression links TLR9 to autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis, where self-DNA recognition drives chronic inflammation.

References
https://pubmed.ncbi.nlm.nih.gov/14716310/ https://pubmed.ncbi.nlm.nih.gov/15307186/

Reference Table for Selecting PVDF Membrane Pore Size Specifications

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%